Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.



Editors' Choice:
Activating β-Catenin with NCAM
Nancy R. Gough (26 July 2011)
Sci. Signal. 4 (183), ec205-ec205. [DOI: 10.1126/scisignal.4183ec205]
Abstract »  
Posted E-Letters:

GSK-3 and β-catenin

Dear Nancy,

Your Editors' Choice on the effect of N-CAM on β-catenin failed to note that the phosphorylation state of GSK-3 (either alpha or β) has no effect on β-catenin levels in cells. Phosphorylation of Serine 9 (GSK-3β) or Serine 21 (GSK-3alpha; both kinases are equivalent in their capacity to regulate β-catenin) is irrelevant to β-catenin phosphorylation. Moreover, potent agonists of Serine 9/21 phosphorylation have little, if any, effect on β-catenin levels. N-CAM may well be modulating β-catenin levels by some mechanism, but it is very unlikely to be achieving this via serine phosphorylation of GSK-3 since it is only the 5% or so of cellular GSK-3 associated with Axin that is relevant to β-catenin regulation. Indeed, genetic reduction of total GSK-3 levels to just 25% of normal (far higher levels of inhibition than can be achieved through serine phosphorylation) leaves β-catenin regulation intact.

There is a plethora of papers that correlate serine phosphorylation of GSK-3 with stabilization of β-catenin. However, correlation does not make for a direct connection and there are compelling genetic data to suggest no connection between these phenomena.


Jim Woodgett

James R. Woodgett
Samuel Lunenfeld Research Institute

To Advertise     Find Products

Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882